The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new
antibiotics' by the Office of Health Economics (OHE).
OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire
research and development process for a new antibiotic.
The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics.
In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising
pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing
AMR research.
Take New Year resolution to stay sober and clean. Difficult but not impossible! Here are following goals to help you keep your resolution through the year. Learn how to stick to your New Year resolution in New Horizon Recovery's latest blog.
Take New Year resolution to stay sober and clean. Difficult but not impossible! Here are following goals to help you keep your resolution through the year. Learn how to stick to your New Year resolution in New Horizon Recovery's latest blog.
Independent charity group, Pharmacist Support has appointed five new trustees to its board - David Downham, Karen Harrowing, Mohammed Hussain, Mala Khiroya, and Alison Scowcroft, for a term of three years.
The new recruits will join the existing Board members Anita Cawley, Catherine Harper, Paul Johnson, Steve Lutener, Esther Sadler-Williams, Mark Sweeney and Sarah Willis.
Harrowing, Downham and Hussain have begun their 3-year term in January 2022, while Scowcroft and Khiroya would join the board in June.
The new appointments are in line with the Charity's plans, announced last year, to enhance its volunteer schemes.
"Since the launch of the charity's new strategy in January 2020, the profession has been faced with many new challenges. We are really proud of the work we have done in the last few years to address some of these challenges," said Pharmacist Support chief executive Danielle Hunt.
England won't have any new Covid-19 restrictions before the end of 2021, health secretary Sajid Javid said on Monday (December 27) whilst the government awaits more evidence on whether the NHS can cope with high infection rates in the new year.
"There will be no further measures before the new year," Javid told reporters, adding: "When we get into the new year, of course we will see then whether we do need to take any further measures."
He said that the highly transmissible Omicron variant of the virus now accounted for around 90 per cent of cases across England and urged people to celebrate new Year
cautiously.
The government's attention is focused on the number of patients being hospitalised with Omicron after early data last week suggested the variant carried a lower
risk of admission.
The latest data showed the number of patients in hospital in England with Covid-19 was its highest since March, at 8,474, but a long way off peaks above 34,000 in January.
A combination of factors, including Britain's vaccination programme, the lag between infections and hospitalisations and the potentially less harmful effects of the Omicron variant have all been put forward by health experts as possible explanations for lower numbers.
Boots UK is set to start recruiting for a new superintendent pharmacist as Marc Donovan moved into a new role.
The company announced the appointment of Anne Higgins as the new pharmacy director for Boots UK. A Boots veteran for 25 years, she has been in the role of director
for stores for more than two years since starting her journey as a pre-register pharmacist in July 1997.
Marc Donovan will be moving into the new role of director of healthcare development and public affairs for Boots. Earlier this year Donovan was appointed the Order
of the British Empire (OBE) "for services to pharmacy" in the Queen's Birthday Honours list.
Donovan and Higgins will be reporting to Jamie Kerruish, the director of healthcare at Boots UK.
A Boots spokesperson told Pharmacy Business: "We will be recruiting for a new superintendent pharmacist and once this appointment is made, Marc will hand over his
superintendent responsibilities"
Former Prime Minister Theresa May has formally opened new offices of LEO Pharma UK and Ireland during a launch event in Maidenhead, Berkshire.
The company said on Friday (June 16) that the new building, based at Foundation Park, will function as its UK and Ireland operational headquarters.
LEO Pharma has been manufacturing dermatology products in the UK and Ireland for over 60 years and continues its commitment to the Maidenhead area, where it been
based for 10 years. The grounds offer state-of-the-art facilities and a greener and more sustainable workplace, the company said and hoped that that strong transport
connections at Foundation Park will allow for seamless international collaboration, while a range of health and wellness initiatives will contribute to employee
wellbeing.
This new space will enable a collaborative and flexible work environment for LEO Pharma staff, ensuring they can continue to work to improve the lives of people
living with skin conditions, their families and society.
The new board of the National Pharmacy Association (NPA) has adopted 10 principles for transforming the contractual framework in England.
The board met for the first time in April, believes that the current Community Pharmacy Contractual Framework is failing NPA members, the wider sector, the NHS,
Government and patients.
The association's new vice chair, Jay Badenhorst, said: "We can't wait until the current framework limps to its finish line in 2024 before giving serious thought
to the new race we must all run in the future."
"Before negotiations for a new contract begin in earnest, we want to make our position clear to all of those who will be involved in its development. Years more
of the same would be totally unacceptable. Tinkering at the edges of the current arrangements as the basis for a new deal could not achieve the transformation
that is needed."
Former chair of the NPA, Andrew Lane, listed some of the principles in a speech to industry leaders in January, but this is the first time the approach has been
agreed in its entirety, following months of testing with NPA members.
The Royal Pharmaceutical Society (RPS) and National Pharmacy Association (NPA) have both urged the new health secretary Steve Barclay to back the 'pharmacy first'
approach in England as mentioned by his predecessor on numerous occasions.
"Sajid Javid recognised the vital role of community pharmacy and the potential of a 'Pharmacy First' to support patient access to care. I would urge the new Health
Secretary to see this through to completion," said chair of RPS in England Thorrun Govind.
Thorrun hopes the new health secretary will engage with pharmacy leaders about how we can make the most of our health and care workforce to support the NHS recovery,
including reducing health inequalities, managing the growing cost of long-term conditions, and utilising the enhanced skills of Pharmacist Independent Prescribers.
Commenting on the new appointment, she said: "This is a crucial time for the future of health and care - with continued pressures on teams, changes to NHS structures
and organisations, and the need for long-term investment in the workforce.
"With a 'refresh' of the NHS Long-Term Plan and the Government's workforce plan expected later this year, these must support a more ambitious approach to advancing
the clinical role of pharmacists across the NHS to better meet changing patient demand, backed by investment in pharmacy education and training.
The British scientist who led the research underpinning AstraZeneca's coronavirus vaccine said at the weekend that a new jab could be developed against the emerging Omicron variant "very rapidly" if needed.
Professor Andrew Pollard, director of the Oxford Vaccine Group, also said existing vaccines should work against the new strain, but that would only become apparent
after more research in the coming weeks.
"It's extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year (with the Delta variant) is going to happen," he told BBC radio.
But if required, "The processes of how one goes about developing a new vaccine are increasingly well-oiled, so if it's needed that is something that could be moved very rapidly."
In a statement, AstraZeneca said it had "developed, in close collaboration with Oxford University, a vaccine platform that enables us to respond quickly to new variants that may emerge".
Balmedie Pharmacy based in Aberdeenshire, Scotland has been purchased by local expanding multiple operator JMF Healthcare.
Balmedie Pharmacy is a well-performing community pharmacy that dispenses an average of 5,255 items per month. It lies completely unopposed in the large Aberdeenshire
village of Balmedie, which is circa eight miles north of Aberdeen City Centre.
The pharmacy has been owned by Brian Arris since 2004 and was recently brought to market to allow him to pursue other pharmacy business opportunities.
Following a confidential sales process with Christie & Co, JMF Healthcare to benefit from new housing developments in this area of Aberdeenshire such as 300 new
homes planned in Balmedie, approved plans for up to 500 new homes in Trump Menie Estate, and 284 new homes planned in Blackdog Village.
Brian Arris, previous owner of Balmedie Pharmacy, comments, "I'm sad to see the business go as the excellent staff have helped grow the pharmacy from scratch since
2004 and we've all put our hearts and souls into providing good pharmaceutical care for the village and surrounding area. I'm confident everyone is left in safe
hands with John at the helm now."
The General Pharmaceutical Council (GPhC) recently appointed a chief pharmacy officer and a chief enforcement officer on 26 October.
Roz Gittins will be joining as chief pharmacy officer and deputy registrar whereas Dionne Spence as chief enforcement officer and deputy registrar from 3 January.
The regulator confirmed that the new officers will "form the new executive structure of the GPhC".
They will be working with the existing staff members Mark Voce, in his new role, is the chief strategy officer and deputy registrar and Jonathan Bennetts,
will be the chief operating officer & deputy registrar.
It is stated that Gittins is to serve as "the most senior member of the profession," offering pharmacy leadership throughout the GPhC.
The fusion of the unique in-depth understanding of medicines by pharmacists together with the competence to prescribe offers will improve access to care and
increase capacity in the health system, said the Royal Pharmaceutical Society (RPS) Director for England Ravi Sharma to Parliament at the Health and Social Care
Select Committee's inquiry on workforce on Monday (May 23).
However, he also stated that a new workforce strategy must support and harness the skills of pharmacist independent prescribers in clinical care with investment
in training, both for new and existing workforce; access to supervisors; protected learning and development time; and commissioning of services to make best use of
independent prescribers across care settings, supported by appropriate prescribing budgets in community pharmacy.
"We're about to see new generation of pharmacists independent prescribers that will make a huge difference to the clinical role of pharmacists to support patient care, but this must be underpinned by protected learning time and a more ambitious approach to commissioning new services to use their skills," Ravi said.
He spoke to MPs in Parliament at the Health and Social Care Select Committee's inquiry on workforce, highlighting the vital contribution of pharmacy teams during
the pandemic and called for action to support the current and future workforce.
Some of the key issues highlighted in the parliament included, the risk of burnout and the need to help boost staff retention; staff wellbeing, including a zero tolerance of abuse from the public; the importance of professional development and protected learning time to enhance patient care and support rewarding careers; the potential of new pharmacist independent prescribers and the need for investment in the current workforce and the need for better workforce data and a pharmacy workforce strategy.
The National Institute for Health and Care Excellence (NICE) has recommended first new treatment - 'romosozumab' for osteoporosis for over a decade.
Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment - romosozumab - after
NICE published the final draft guidance.
Over 20,000 people could be eligible for the treatment according to the company. Clinical trial evidence showed that romosozumab (also known as EVENITY and made by
UCB) followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone.
Osteoporosis is a disease that causes bones to become thin and fragile. Many people with osteoporosis show no symptoms, but they may be at increased risk of fracture.
Osteoporosis leads to nearly 9 million fractures around the world each year, and over 300,000 people per year attend hospitals in the UK with fractures caused by
osteoporosis.
Alliance Healthcare, the UK's largest pharmaceutical wholesaler, announced today (December 7) the appointment of Marie Evans as its new managing director.
Evans, who is the current commercial and category director of the firm, will report to Juan Guerra, Alliance Healthcare's senior vice president and managing director of International Wholesale.
Commenting on the new appointment, Guerra said: "The last 18 months has shown just how important wholesale and distribution is to the NHS and I am so excited to
welcome Marie to her new position at this critical time.
"Her experience and leadership will be key as we continue to evolve our services in response to the changing needs of pharmacy, the health service, and industry."
The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics.
On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model.
Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face.
"To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.
Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China witness a
rise in infections, the head of the World Health Organization said on Friday (December 2).
The comments by WHO Director-General Tedros Adhanom Ghebreyesus mark a change in tone just months after he said that the world has never been in a better position
to end the pandemic.
"We are much closer to being able to say that the emergency phase of the pandemic is over, but we're not there yet," Tedros said on Friday.
The global health agency estimates that about 90% of the world's population now has some level of immunity to SARS-COV-2 either due to prior infection or vaccination.
"Gaps in testing … and vaccination are continuing to create the perfect conditions for a new variant of concern to emerge that could cause significant mortality,"
Tedros said.
COVID-19 infections are at record highs in China and have started to rise in parts of Britain after months of decline.
The Community Pharmacy England Committee has adopted a new approach to engagement with sector by inviting all pharmacy owners to share their views on
pharmacy's finances, pressures and capacity ahead of its meeting in July.
It has sought views of pharmacists via short poll by Sunday (2 July) and will have a discussion on the poll results at the meeting before reporting back to the
sector afterwards.
The key focus for July Committee Meeting will be to make most of £645m for the community pharmacy sector, and also on the ongoing work to make the wider case for
more investment in the sector.
This new way of working follows association's rebrand on 30th May which signalled the start of its new approach to engagement to help them to build stronger
relationships with pharmacy owners.
The association hopes this new approach will help them better engage with members and listen to pharmacy's views better.
The Department of Health and Social Care (DHSC) has introduced new arrangements for the application of discount deduction to community pharmacy payments which
will be implemented in six financial quarters beginning in October 2022 and concluding in January 2024.
Under the new discount deduction system, the current single scale will be split into three groups: one each for generic medicines, branded medicines, and appliances.
Separate fixed deduction rates have been determined for each group.
This will provide all pharmacies the same rates of deduction applied to their reimbursement for the three different groups, regardless of the total value of that
reimbursement.
Fin McCaul, PSNC member and independent community pharmacy contractor, said: "The discount deduction scale has been a point of contention for contractors for many
years, and PSNC has long been pushing to remedy this.
"The incoming changes are designed to both improve equity of access to margin and manage the distortions presented by branded medicines, which just don't have the
same level of discount available as generics.
The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission.
UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week.
The new initiative will capitalise on the UK's unique strengths in securing "health data and cutting-edge AI."
It will also help to identify those at risk of "dementia" and will ensure that patients participate in the trials at the right time to develop new treatments
effectively.
Henceforth, it will provide us with better data on how well new therapies work.
Sunak said: "AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer."